

Creating a Values based, R&D driven Global Biopharmaceutical Leader

December 5, 2018

Christophe Weber

President & CEO

Takeda Pharmaceutical Company Limited



Better Health, Brighter Future

Important Notice



For the purposes of this notice, “presentation” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“**Takeda**”) during the presentation. This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares are being offered to the public by means of this presentation. This presentation is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

Unless specified otherwise, no statement in this presentation (including any statement of estimated synergies) is intended as a profit forecast or estimate for any period and no statement in this presentation should be interpreted to mean that earnings or earnings per share for Takeda for the current or future financial years would necessarily match or exceed the historical published earnings per share for Takeda.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this presentation, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This presentation and any materials distributed in connection with this presentation may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. In particular, this presentation contains forecasts and management estimates related to the financial and operational performance of Takeda, including statements regarding forecasts for FY2018 revenue, Core Earnings, Operating profit, Profit before income taxes, Net profit attributable to owners of Takeda, Basic earnings per share, R&D expenses, Amortisation and impairment and other income/expense, Underlying Revenue, Underlying Core Earnings and Underlying Core EPS. Without limitation, forward looking statements often include the words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or words or terms of similar substance or the negative thereof. Any forward-looking statements in this document are based on the current assumptions and beliefs of Takeda in light of the information currently available to it. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takeda’s business, including general economic conditions in Japan, the United States and worldwide; competitive pressures and developments; applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; changes in exchange rates; claims or concerns regarding the safety or efficacy of marketed products or products candidates; and post-merger integration with acquired companies, any of which may cause Takeda’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. Neither Takeda nor its management gives any assurances that the expectations expressed in these forward-looking statements will turn out to be correct, and actual results, performance or achievements could materially differ from expectations. Persons receiving this presentation should not place undue reliance on forward looking statements. Takeda undertakes no obligation to update any of the forward-looking statements contained in this presentation or any other forward-looking statements it may make. Past performance is not an indicator of future results and the results of Takeda in this presentation may not be indicative of, and are not an estimate, forecast or projection of Takeda’s future results.

Medical information

This presentation contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

Profit Forecast for Takeda for the year ending March 31, 2019

Takeda is currently in an offer period (as defined in the City Code on Takeovers and Mergers (the “Code”)) with respect to Shire plc. Pursuant to Rule 28 of the Code, statements made regarding Takeda’s guidance for FY2018 (including statements regarding forecasts for FY2018 revenue, Core Earnings, Operating profit, Profit before income taxes, Net profit attributable to owners of Takeda, Basic earnings per share, R&D expenses, Amortisation and impairment and other income/expense, Underlying Revenue, Underlying Core Earnings and Underlying Core EPS) constitute a profit forecast for the year ending March 31, 2019 (the “Takeda Profit Forecast”).

For additional information regarding the Takeda Profit Forecast and the required statement by its Directors that such profit forecast is valid and has been properly compiled on the basis of the assumptions stated and that the basis of accounting used is consistent with Takeda’s accounting policies, please see page 9 of Takeda’s Summary of Financial Statements (Tanshin) for the Six Months Period Ended September 30, 2018.

A photograph of a woman with dark hair hugging a young girl with dark hair from behind. They are outdoors, with a tree trunk visible on the left and a blurred green background. The image is overlaid with a semi-transparent white rectangle containing text.

VISION 2025

**Our mission is to strive towards
Better Health and a Brighter Future
for people worldwide through
leading innovation in medicine**

We serve the needs of our patients, wherever they are.

We earn the trust of society and customers through Takeda-ism.

**We are recognized as best in class because of agility and
innovation, qualities that help us build a steady pipeline and
deliver growth, year on year.**

Our long history since 1781 has shaped the values that are fundamental to the success of Takeda in the long term

VALUES



We take action and make decisions by focusing on our four priorities, in order of:

1

Putting the patient
at the center



2

Building trust
with society



3

Reinforcing
our reputation



4

Developing
the business

Takeda has created a unique R&D engine

THERAPEUTIC AREA FOCUS

Oncology, Gastroenterology, Neuroscience plus Vaccines

PARTNERSHIPS & CAPABILITIES

TRANSFORM OUR CULTURE

R&D TRANSFORMATION KEY IMPERATIVES

- Agile and lean
- Dynamic and sustainable research and early development engine
- Transformative advances via reciprocally advantageous partnerships
- Laser-focused on purposeful execution

With a very focused and lean footprint freeing up resources for pipeline development



BOSTON, MA

R&D Center
Oncology, GI Research



SHONAN, JAPAN

Neuroscience Research,
T-CiRA, iPark



SAN DIEGO, CA

Specialized drug
discovery technologies,
GI and Neuroscience

Resulting in a dynamic and re-invigorated pipeline

ONCOLOGY

PHASE 1			PHASE 2	PHASE 3 / FILED	Approved*	
TAK-981 SUMO inhibitor Multiple cancers	TAK-573 Teva Anti-CD38 antineoplastic R/R MM	XMT-1522 Mersana Therapeutics HER2 dolaflexin ADC HER2+ Solid Tumors	sapanisertib mTORC 1/2 inhibitor Endometrial Cancer	pevonedistat NAE inhibitor HR-MDS/CMML/LB AML	NINLARO Proteasome inhibitor Anti-multiple myeloma, R/R MM R/R MM relapsed, R/R MM post-SCT Relapsed MM post-SCT	ADCETRIS Seattle Genetics CD30 ADC FL HL, FL PTCL, R/R HL, SALCL
TAK-164 ImmunoGen GCC IG1 ADC GI cancer	TAK-079 Anti-CD38 mAb R/R MM, SLE	TAK-788 EGFR/HER2 inhibitor NSCLC	TAK-659 SYK/FLT-3 inhibitor DLBCL, Solid Tumors	relugolix Myovant GnRH antagonist Prostate Cancer (JP) (Phase 1 in CN)	ALUNBRIG ALK inhibitor 2L ALK+ NSCLC, 1L ALK+ NSCLC	ICLUSIG BCR-ABL inhibitor 2L Chronic Phase CML, Ph+ ALL
			TAK-931 CDC7 inhibitor mCRC, ESCC, sqNSCLC		Cabozantinib Exelixis VEGFR/RTK inhibitor 2 nd line RCC, HCC (JP)	Niraparib Tesaro PARP 1/2 inhibitor Multiple cancer (JP)

GASTRO-ENTEROLOGY

TAK-671 Samsung Bioepis Protease Inhibitor Acute Pancreatitis	Kuma062 PVP Biologics Glutenase Celiac Disease	TIMP-Gliadin Cour Imm. Tol. Induction Celiac Disease	TAK-906 D2/D3R Antagonist Gastroparesis	ENTYVIO a497 mAb UC/CD, adalimumab H2H, Sub-Q UC, Sub-Q CD, GuHD Prophylaxis	Vonoprazan PCAB GERD PPI partial resp, ARD, NERD
TAK-018 Enterome FimH antagonist Crohn's Disease			TAK-954 Theravance Biopharma 5-HT4R agonist EFI		ALOFISEL mesenchymal stem cells Perianal Fistulas in CD

NEURO-SCIENCE

TAK-653 AMPA potentiator TRD	TAK-418 LSD1 inhibitor Kabuki Syndrome	TAK-041 GPR139 agonist CIAS NS	TAK-935 Ovid Therapeutics CH24H inhibitor Rare Pediatric Epilepsies	TRINTELLIX™ Lundbeck Multimodal anti-depressant MDD (JP)
MEDI-1341 AstraZeneca Alpha-syn mAb Parkinson's Disease	TAK-925 Orexin 2R agonist Narcolepsy		TAK-831 DAAO inhibitor Ataxia, CIAS NS	
WVE-120101 Wave mHTT SNP1 ASO Huntington's Disease	WVE-120102 Wave mHTT SNP2 ASO Huntington's Disease			

VACCINES

TAK-021 EV71 Vaccine	TAK-426 BARDA Zika Vaccine	TAK-195 Gates Foundation Inactivated Polio Vaccine	TAK-003 Dengue Vaccine
		TAK-214 Norovirus Vaccine	

Orphan Drug Designation
(in any region / indication for a given asset)

Assets shown in Phases 1-3 explicitly refer to new molecular entities

* With active development seeking new or supplemental indications, or approvals in new territories

31 pipeline assets progressed since the start of FY2016

46% of pipeline is partnered

83% of pipeline with global development plans/rights

37% of pipeline has orphan drug designation

Shire acquisition will enhance Takeda R&D engine with an initial R&D budget greater than 400 Bn yen



TA



TA



TA



TA

4 TA
(Therapeutic Areas)



+ 2

With the potential to deliver more value in the future

Takeda

Shire

Orphan Drug Designation

	PHASE 1		PHASE 2		PHASE 3/FILED		APPROVED*		
ONCOLOGY	TAK-573 Teva Anti-CD38-attenukine Refractory MM	XMT-1522 Mersana Therapeutics HER2 dotaflexin ADC HER2 + solid tumors	sapanisertib mTORC 1/2 inhibitor Breast cancer	TAK-659 SYK inhibitor DLBCL	relugolix Myovant GNRH antagonist Prostate Cancer (JP)	pevonedistat NAE inhibitor HR MDS	NINLARO® Proteasome inhibitor MM R/R (EM), R/R Amyloidosis, Front Line MM, R/R Myeloma doublet regimen Maintenance MM, post-SCT Maintenance MM w/S SCT	ADCETRIS® Seattle Genetics CD30 ADC FL HL, FL MTCL, CTCL	ICLUSIG® BCR-ABL inhibitor Imatinib resistant Chronic Phase CML Second-Line Chronic Phase CML, Ph ALL
	TAK-079 Anti-CD38 mAb Refractory MM	TAK-788 EGFR/HER2 inh NSCLC	TAK-931 CD7 inhibitor Solid Tumors				ALUNBRIG® (brigatinib) ALK inhibitor ALK+NSCLC (EU), FL ALK+ NSCLC	cabozantinib Exelixis VEGFR/RTK inhibitor Solid tumors (JP)	Niraparib Tesarro PARP 1/2 inhibitor Multiple cancer (JP)
GI	TIMP-Gliadin Cour Imm Tol Induction Celiac Disease		TAK-906 D2/D3R Antagonist Gastroparesis	TAK-954 Theravance Biopharma 5-HT4R ag Enteral Feeding Intolerance	SHP621 BOS EoE	SHP647 MAdCAM-1 mAb IBD	ENTYVIO® s497 mAb UC/CD (EM), UC (JP), CD (JP), adalmumab H2H Sub-Q UC, Sub-Q CD, GVHD Prophylaxis, GVHD SR, IO Colitis	Vonoprazan PCAB ARD (Asia), NERD (JP) PPI Partial Responder	AMITIZA® Sucampo Chloride channel activator Pediatric constipation , New formulation
			SHP625 ASBTI PFIC, Alagille's	SHP626 ASBTI NASH			ALOFISEL Tigenix mesenchymal stem cells Perianal Fistulas in CD	GATTEX GLP-2 SBS	RESOLOR prucalopride CIC
NEURO-SCIENCE	TAK-653 AMPA potentiator TRD	TAK-418 LSD1 inhibitor Kabuki Syndrome	TAK-935 Ovid Therapeutics CH24H inhibitor Rare Pediatric Epilepsies	TAK-831 DAAO inhibitor SCZ, Ataxia			TRINTELLIX™ Lundbeck Multimodal anti-depressant Cognition data in label (CRL received) MDD (JP)	BUCCOLAM seizures	VYVANSE ADHD
	MEDI-1341 Astra Zeneca Alpha-syn mAb Parkinson's Disease	TAK-925 Orexin 2R agonist Narcolepsy						MYDAYIS ADHD	
	SHP680 Neurologic Conditions	TAK-041 GPR139 agonist CIAS neg. symptoms							
RARE DISEASES	SHP611 ERT MLD	SHP631 ERT Hunter CNS	SHP607 IGF-1/IGFBP3 Chronic Lung Disease		Lanadelumab Anti-kallikrein mAb HAE	SHP620 CMV infection in transplant patients	FIRAZYR HAE	VONVENDI vWD	CINRYZE HAE, AMR
	SHP654 Gene therapy HemA				SHP609 Hunter (IT)	SHP655 ERT/ ADAMTS-13 CTTP	OBIZUR CHAWI Surgery		
PLASMA-DERIVED THERAPIES							HYQVIA Pediatric PID, CIDP		
VACCINES	TAK-021 EV71 Vaccine	TAK-426 BARDA Zika Vaccine	TAK-195 Gates Foundation Inactivated Polio Vaccine	TAK-214 Norovirus Vaccine		TAK-003 Dengue Vaccine			
OPHTHAL-MOLOGY	SHP639 Glaucoma		SHP659 DED			SHP640 Infectious conjunctivitis	XIIDRA DED		

Accelerates Takeda transformation with a more distinctive focus on key therapy areas


ONCOLOGY	GI	NEUROSCIENCE	RARE DISEASES			PLASMA DERIVED THERAPIES	OTHERS (example of key products)
			LYSOSOMAL STORAGE DISORDERS	HAE ²	HEMATOLOGY		
 	 	 				kenketu glovenin[®]-I KENKETU NONTHRON[™] KENKETU ALBUMIN	Nesina[®] alogliptin Colcrys[®] colchicine, USP tablets AZILVA[®] Neosaldina[®] Magnyl Ebrantil Xefo ...etc.
	 	 BUCCOLAM[®]	 	 	 	 	 ...etc.

~75%
Total Sales¹

Source: Shire plc Annual Report 2017, Takeda Consolidated Financial statements for the Fiscal Year Ended March 31, 2017

Notes: Percentage calculated using (a) the amount for the 12 month period ending on March 31, 2017 and converted using the \$/¥ of 111.43 as at that date (in the case of Takeda) and (b) the amount for the 12 month period ending on December 31 2017 and converted using the \$/¥ of 112.65 as at that date (in the case of Shire). 1Management Data. 2Hereditary Angioedema

Create an attractive geographic footprint with leading positions in Japan and the U.S.



Source: Shire plc Annual Report 2017 and management information, Takeda Consolidated Financial statements for the Fiscal Year Ended March 31, 2017, Takeda Consolidated Financial statements for the Nine Month Period Ended December 31, 2017

Notes: Percentages calculated using (1) the revenue by geography for the 12 month period ending on December 31, 2017 (the final quarter of FY2016 and the first three quarters of F2017) and converted using the \$/¥ of 1:112.65 as at that date (in the case of Takeda) and (2) the revenue by geography for the 12 month period ending on December 31, 2017 (in the case of Shire). Percentages for the combined group are calculated by aggregating the revenue by geography for Takeda and Shire. The historical revenue of the combined group represent the aggregate consolidated revenue of (a) the amount for the 12 month period ending on March 31, 2017 and converted using the \$/¥ of 1:112.65 as at that date (in the case of Takeda) and (b) the amount for the 12 month period ending on 31 December 2017 and converted using the \$/¥ of 1:112.65 as at that date (in the case of Shire). These results are historic and do not take into account any divestures or other events that may have occurred since these dates. The aggregate revenue figure comprises the aggregate of Takeda's reported revenue and Shire's Non GAAP revenue.


Transaction will be significantly EPS accretive and generate strong cash flow

- The recurring pre-tax cost synergies for the combined group are expected to reach a run-rate of at least ¥153bn / \$1.4bn per annum by the end of the third fiscal year following completion¹
- The number of issued Takeda shares will essentially double but EBITDA² is approximately three times larger on a historical combined basis³.
The acquisition will be significantly EPS accretive⁴ on an underlying basis from the first full fiscal year following completion and on a reported basis within 3 fiscal years post completion.
- Low risk of impairments to combined goodwill (¥4,000 bn to ¥4,400 bn) and intangible assets (¥6,300 bn to ¥6,700 bn)
- The transaction's Return on Invested Capital (ROIC) is expected to exceed Takeda's weighted average cost of capital (WACC) within the first full fiscal year following completion
- Intend to maintain our well-established dividend policy with 180 JPY dividend per share
- Committed to maintaining investment grade credit rating


Notes: ¹ The Takeda Directors expect recurring pre-tax cost synergies for the Combined Group to reach a run - rate of at least \$1.4 billion per annum by the end of the third fiscal year following completion of the Acquisition (\$/¥ of 1:108.97 as at May 8, 2018). Reported under Rule 28.1 of the Takeover Code; related reports can be found in the Rule 2.7 Announcement made by Takeda on May 8, 2018, as well as information regarding the method of calculation of the synergies and the costs to achieve such synergies. ² Earnings Before Interest Taxes Depreciation and Amortization ³ The historical pro-forma EBITDA figure comprises Takeda's EBITDA (Operating Profit adjusted for other operating income and expenses, intangible amortization & impairment, software amortization, PP&E depreciation & impairment and other non-recurring items) for the Fiscal Year Ended March 31, 2018 based on the exchange rates of \$:¥ of 1:108.97 as at May 4, 2018 and Shire's EBITDA for the 12 month period ending on Mar 31, 2018 (the final three quarters of FY2017 and the first quarter of FY2018). ⁴ The statement that the Acquisition is underlying earnings accretive is not intended as a profit forecast and should not be construed as such, and is therefore not subject to the requirements of Rule 28 of the Takeover Code. The statement should not be interpreted to mean that the earnings per share in any future fiscal period will necessarily match or be greater than those for the relevant preceding financial period.

Committed to investment grade with a target net debt to EBITDA ratio of 2.0x or less in the medium term

Net Debt Build Up (bn¹)




Illustrative Net Debt / EBITDA Ratio



Takeda has a strong track record in deleveraging and portfolio optimisation

Notes: ¹ Net debt converted based on the exchange rate of ¥:¥ of 1:113.6 as at Sep 30, 2018, ² New debt expected to be raised in order to finance the acquisition of Shire, ³ Illustrative pro forma net debt / EBITDA of 4.8x calculated using the illustrative pro forma net debt of ~\$48.0bn. The EBITDA is calculated by adding : i) Takeda's EBITDA (Operating Profit adjusted for other operating income and expenses, intangible amortisation & impairment, software amortisation, PP&E depreciation & impairment and other non-recurring items) of \$3,552mm as per Consolidated Financial statements for the Fiscal Year Ended March 31, 2018 released on May 14, 2018 and based on the exchange rates of ¥:¥ of 1:106.35 as at March 31, 2018; and ii) Shire's EBITDA of \$6,523mm for the 12 month period ending on March 31, 2018 (the final three quarters of FY2017 as disclosed in Shire's year end results released on Feb 14, 2018 and the first quarter of FY2018 as disclosed in Shire's Q1 results released on Apr 26, 2018), ⁴ Based on forecast net debt taking into account the expected cash balance, annual cash generation and forecast FY EBITDA, ⁵ Based on forecast net debt taking into account the expected cash balance, annual cash generation, an illustrative \$10bn of divestitures (post-tax) and forecast FY EBITDA (adjusted for divestitures)

Financing supported by leading global financial institutions



Note: ¹ ¥500 billion (approx. \$4.5 billion) senior short term loan entered into on 26 October 2018 (which will in turn be refinanced using a ¥500 billion (approx. \$4.5 billion) hybrid loan, also entered into on 26 October 2018)

Board of Directors for Best-in-Class Governance

INTERNAL DIRECTORS



NC

Christophe Weber

Representative Director,
President & CEO



Masato Iwasaki

Director,
JPBU President



Andrew Plump

Director, Chief Medical
& Scientific Officer

CC

**Compensation
Committee**

NC

**Nomination
Committee**



**Independent
External Director**

EXTERNAL DIRECTORS



NC

Masahiro Sakane

Independent Director
Chair of the Board meeting
Chair of Nomination Committee



Michel Orsinger

Independent Director



CC

Toshiyuki Shiga

Independent Director
Chair of Compensation
Committee



NC

Emiko Higashi

Independent Director



CC

Yoshiaki Fujimori

Independent Director

DIRECTORS ON THE AUDIT & SUPERVISORY COMMITTEE (A&SC)



CC

Yasuhiko Yamanaka

Director,
A&SC member



NC

Shiro Kuniya

Independent Director,
Chair A&SC



Koji Hatsukawa


Independent Director,
A&SC member



Jean-Luc Butel

Independent Director,
A&SC member

Takeda board (BOD) and Takeda Executive Team (TET) have been fully involved early in the acquisition with many reviews starting in 2017



The acquisition has been approved by the board after multiple extensive reviews with detailed risk assessment

MAJOR RISKS



Financial Market Risks

Examples:

- Interest rate risk
- Currency risk

MITIGATION

- Remain investment grade credit rated
- Denominate the debt with competitive aggregate interest rate with the right currency balance
- Consider disposal of non-core assets



Business Risks

Examples:

- Competitive pressure
- Pricing pressure

- Model future business outlook with prudent forecasts
- Risk of impairments to goodwill and intangible assets mitigated by Shire's in market products and prudent forecasts also applied to its pipeline



Integration Risks

Examples:

- Cultural difference
- Shire talent retention

- Experienced leadership well prepared for integration
- Keep consistent with Takeda's name, culture and purpose
- Promote shared intention to become a patient centric and R&D driven company
- Build the operating model to leverage Takeda and Shire employee know-how

Integration planning is well underway

Creating our new operating model to leverage Takeda and Shire know-how

PRINCIPLES

Patient-centric

- Developing more innovative medicines through a leading R&D engine
- Getting closer to patients and meeting their unique needs in each market

Agile & Simple

- Continuing to be LOC*-centric empowering General Managers to make local decisions
- Minimizing complexity

*Local Operating Company

Lean & Focused

- Focusing on six business drivers
- Leveraging global scale while keeping the right balance of country resources
- Making us fit to deal with demanding healthcare environments

4 Regional
Business
Units

3 Global
Specialty
Business Units



PDT*
BU



Oncology
BU



Vaccine
BU

*Plasma Derived Therapies

Global, diverse and experienced new Takeda Executive Team (Post-closing)



**CHRISTOPHE
WEBER**
President & CEO



**COSTA
SAROUKOS**
Global Finance



HARUHIKO HIRATE
Corporate
Communication &
Public Affairs



**YOSHIHIRO
NAKAGAWA**
Global Legal



**PADMA
THIRUVENGADAM**
Global Human
Resources



MILANO FURUTA
Corporate Strategy



MWANA LUGOGO
Global Ethics &
Compliance



**RAMONA
SEQUEIRA**
U.S. Business Unit



MASATO IWASAKI
Japan Pharma
Business Unit



GILES PLATFORD
Europe & Canada
Business Unit



RICARDO MAREK
Emerging Markets
Business Unit



**CHRISTOPHE
BIANCHI**
Global Oncology
Business Unit



**RAJEEV
VENKAYYA**
Global Vaccine
Business Unit



JULIE KIM¹
Global Plasma-
Derived Therapy
Business Unit



ANDY PLUMP
R&D



**THOMAS
WOZNIEWSKI**
Global Manufacturing
and Supply



**GERARD (JERRY)
GRECO**
Global Quality



**CAMILLA
SOENDERBY¹**
Global Patient Value
& Product Strategy



**MARCELLO
AGOSTI**
Global Business
Development



HELEN GIZA
Integration

Reinforce the diversity and strength of the board with appointment of three new independent external directors

INTERNAL DIRECTORS



NC

Christophe Weber

Representative Director,
President & CEO



Masato Iwasaki

Director,
JPBU President



Andrew Plump

Director, Chief Medical
& Scientific Officer

CC

Compensation
Committee

NC

Nomination
Committee

Independent
External Director

EXTERNAL DIRECTORS



NC

Masahiro Sakane

Independent Director
Chair of the Board meeting
Chair of Nomination Committee



Michel Orsinger

Independent Director



CC

Toshiyuki Shiga

Independent Director
Chair of Compensation Committee



NC

Emiko Higashi

Independent Director



CC

Yoshiaki Fujimori

Independent Director



Ian Clark¹

Independent Director



Olivier Bohuon¹

Independent Director



Steven Gillis¹

Independent Director

DIRECTORS ON THE AUDIT & SUPERVISORY COMMITTEE (A&SC)



CC

Yasuhiko Yamanaka

Director,
A&SC member



NC

Shiro Kuniya

Independent Director,
Chair A&SC



Koji Hatsukawa

Independent Director,
A&SC member



Jean-Luc Butel

Independent Director,
A&SC member



The acquisition of Shire will enable Takeda to significantly accelerate its transformational journey to become a values-based, R&D driven global biopharmaceutical leader headquartered in Japan



Glossary of Abbreviations

AD	Alzheimer's disease	ESCC	esophageal squamous-cell carcinoma	NF	new formulation
ADC	antibody drug conjugate	FL	front line	NK	natural killer
ADHD	attention deficit hyperactivity disorder	FLT-3	FMS-like tyrosine kinase 3	NME	new molecular entity
ALK	anaplastic lymphoma kinase	FSI	first subject in	NSCLC	non-small cell lung cancer
ALS	amyotrophic lateral sclerosis	GCC	guanylyl cyclase C	NSCT	non stem cell transplant
AML	acute myeloid leukemia	GERD	gastroesophageal reflux disease	NS	negative symptoms
AMR	antibody mediated rejection	GI	gastrointestinal	OIC	opioid induced constipation
ASCT	autologous stem cell transplant	GnRH	gonadotropin-releasing hormone	ORR	overall response rate
ARD	acid-related diseases	GU	gastric ulcer	PARP	poly (ADP-ribose) polymerase
BTK	Bruton's tyrosine kinase	GvHD	graft versus host disease	PBS	phosphate buffered saline
BBB	blood brain barrier	HAE	hereditary angioedema	PCAB	potassium competitive acid blocker
BOS	budesonide oral suspension	H2H	head to head	PFIC	progressive familial intrahepatic cholestasis
CAR-T	Chimeric antigen receptor-T	HCC	hepatocellular carcinoma	Ph+ ALL	Philadelphia chromosome-positive acute lymphoblastic leukemia
CD	Crohn's disease	HemA	hemophilia A	PID	primary immunodeficiency
CHAWI	congenital hemophilia A with inhibitors	HER2	human epidermal growth factor receptor 2	PPI	proton pump inhibitor
CIAS	cognitive impairment associated with schizophrenia	HL	Hodgkin's lymphoma	PK	pharmacokinetics
CIC	chronic idiopathic constipation	HR MDS	high-risk myelodysplastic syndromes	POC	proof of concept
CIDP	chronic inflammatory demyelinating polyneuropathy	IBD	inflammatory bowel disease	POI	post-operative ileus
CML	chronic myeloid leukemia	IBS-C	irritable bowel syndrome with constipation	PTCL	peripheral T-cell lymphoma
CMML	chronic myelomonocytic leukemia	IND	investigational new drug	R/R	relapsed/refractory
CSF	cerebrospinal fluid	I/O	immuno-oncology	RA	rheumatoid arthritis
CNS	central nervous system	IV	intravenous	RCC	renal cell cancer
CRL	complete response letter	iPSC	induced pluripotent stem cells	RTK	receptor tyrosine kinase
CTCL	cutaneous T-cell lymphoma	LBD	Lewy body dementia	sALCL	systemic anaplastic large cell lymphoma
CTTP	congenital thrombotic thrombocytopenic purpura	LB AML	low-blast acute myeloid leukemia	SBS	short bowel syndrome
DAAO	D-amino acid oxidase	LSD1	Lysine specific demethylase 1	SC	subcutaneous formulation
DED	dry eye disease	LCM	lifecycle management	SCT	stem cell transplant
DLBCL	diffuse large B-cell lymphoma	mAb	monoclonal antibody	SCZ	schizophrenia
DM	diabetes mellitus	MAOB	monoamine oxidase B	SLE	systemic lupus erythematosus
DU	duodenal ulcer	MLD	metachromatic leukodystrophy	sq	squamous
Dx	diagnosis	NAE	NEDD8 activating enzyme	SR	steroid refractory
EE H	erosive esophagitis healing	NASH	non-alcoholic steatohepatitis	SR-GvHD	steroid refractory acute graft vs host disease
EE M	erosive esophagitis maintenance	ND	newly diagnosed	STING	stimulator of interferon genes
EFI	enteral feeding intolerance	NDA	new drug application	SUMO	small ubiquitin-related modifier
EGFR	epidermal growth factor receptor	Neg	negative	SYK	spleen tyrosine kinase
EOE	eosinophilic esophagitis	NERD	non-erosive reflux disease	TESD	treatment emergent sexual dysfunction